Osaic Holdings’s Verve Therapeutics VERV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-3,344
| Closed | -$37.6K | – | 8199 |
|
|
2025
Q3 | $37.6K | Sell |
3,344
-123
| -4% | -$1.36K | ﹤0.01% | 5498 |
|
|
2025
Q2 | $38.9K | Buy |
3,467
+1,203
| +53% | +$6.86K | ﹤0.01% | 5230 |
|
|
2025
Q1 | $10.3K | Sell |
2,264
-376
| -14% | -$2.52K | ﹤0.01% | 5770 |
|
|
2024
Q4 | $14.9K | Sell |
2,640
-25
| -0.9% | -$141 | ﹤0.01% | 5531 |
|
|
2024
Q3 | $12.9K | Buy |
2,665
+141
| +6% | +$819 | ﹤0.01% | 5657 |
|
|
2024
Q2 | $12.3K | Sell |
2,524
-107
| -4% | -$673 | ﹤0.01% | 5653 |
|
|
2024
Q1 | $34.9K | Buy |
2,631
+726
| +38% | +$9.63K | ﹤0.01% | 4983 |
|
|
2023
Q4 | $26.6K | Sell |
1,905
-2,086
| -52% | -$25.9K | ﹤0.01% | 5330 |
|
|
2023
Q3 | $52.9K | Buy |
3,991
+3,041
| +320% | +$49K | ﹤0.01% | 4968 |
|
|
2023
Q2 | $17.8K | Sell |
950
-14
| -1% | -$233 | ﹤0.01% | 5649 |
|
|
2023
Q1 | $13.9K | Sell |
964
-173
| -15% | -$3.39K | ﹤0.01% | 5782 |
|
|
2022
Q4 | $22K | Sell |
1,137
-1,136
| -50% | -$30.1K | ﹤0.01% | 5503 |
|
|
2022
Q3 | $78K | Buy |
2,273
+1,773
| +355% | +$56.6K | ﹤0.01% | 4576 |
|
|
2022
Q2 | $8K | Buy |
+500
| New | +$7.74K | ﹤0.01% | 6255 |
|
|
2022
Q1 | – | Sell |
-26
| Closed | – | – | 7519 |
|
|
2021
Q4 | $0 | Buy |
+26
| New | +$1.09K | ﹤0.01% | 7586 |
|
Other funds holding VERV
Osaic Holdings's VERV Position: Q4 2025 in Review
Osaic Holdings sold out of Verve Therapeutics (VERV) in Q4 2025, closing a stake of 3,344 shares — an estimated $37.6K sold.
Osaic Holdings first reported a position in VERV in Q4 2021 and held it in 15 quarters. The position peaked at $78K in Q3 2022. 1 fund tracked by Wall St. Rank holds VERV as of Q4 2025.
- Osaic Holdings reported no remaining Verve Therapeutics position as of Q4 2025 after selling out during the quarter.
- Osaic Holdings sold 3,344 Verve Therapeutics shares in Q4 2025, an estimated $37.6K.
- Osaic Holdings first reported a position in Verve Therapeutics in Q4 2021 and held it in 15 quarters.
- Osaic Holdings's Verve Therapeutics position peaked at $78K in Q3 2022.
- 1 fund tracked by Wall St. Rank held Verve Therapeutics as of Q4 2025.
Based on Osaic Holdings's 13F filing for Q4 2025, filed 17 Feb 2026.